The state of the art in the pathogenesis of ATL and new potential targets associated with HTLV-1 and ATL

International Reviews of Immunology

Volumn 26, Issue 5-6, 2007, Pages 249-268

  Murata, Ken ^a   Yamada, Yasuaki ^b  

^a TOTTORI UNIVERSITY   (Japan)

^b NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

ATL; HBZ; HTLV 1; Tax

Indexed keywords

BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR; CHEMOKINE RECEPTOR CCR4; DEATH RECEPTOR; GENOMIC DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCLONAL ANTIBODY; PROTEIN HBZ; TAX PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VIRUS PROTEIN;

APOPTOSIS; BREAST FEEDING; CELL CYCLE REGULATION; CELL PROLIFERATION; DISEASE TRANSMISSION; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; LEUKEMOGENESIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; T CELL LEUKEMIA; TUMOR SUPPRESSOR GENE; VIRUS MORPHOLOGY; VIRUS REPLICATION; VIRUS TRANSCRIPTION; VIRUS TRANSMISSION;

BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; GENE PRODUCTS, TAX; GENES, PX; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; JAPAN; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MUTATION; NF-KAPPA B; RECEPTORS, CCR4; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; VIRAL PROTEINS;

EID: 36249021457     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.1080/08830180701709817     Document Type: Review

References (90)

1. T. Uchiyama, J. Yodoi, K. Sagawa, K. Takatsuki, and H. Uchino, Adult T-cell leukemia: clinical and hematologic features of 16 cases, Blood, 50: 481-492, 1977.
2. B.J. Poiesz, F.W. Ruscetti, A.F. Gazdar, P.A. Bunn, J.D. Minna, and R.C. Gallo, Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma, Proc. Natl. Acad. Sci. U.S.A., 77: 7415-7419, 1980.
3. M. Yoshida, M. Seiki, K. Yamaguchi, and K. Takatsuki, Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease, Proc. Natl. Acad. Sci. U.S.A., 81: 2534-2537, 1984.
4. K. Tajima and T. Takezaki, Ethnoepidemiology of ATL/HTLV in Mongoloids with Special Reference to Mongoloid Dispersal. Gann Monograph on Cancer Research No. 50. Tokyo, Japan: Japan Scientific Societies Press, pp. 277-288, 2003.
5. K. Kinoshita, S. Hino, T. Amagasaki, S. Ikeda, Y. Yamada, J. Suzuyama, S. Momita, K. Toriya, S. Kamihira, and M. Ichimaru, Demonstration of adult T-cell leukemia virus antigen in milk from three sero-positive mothers, Jpn. J. Cancer Res., 75: 103-105, 1984.
6. S. Hino, K. Yamaguchi, S. Katamine, H. Sugiyama, T. Amagasaki, K. Kinoshita, Y. Yoshida, H. Doi, Y. Tsuji, and T. Miyamoto, Mother-to-child transmission of human T-cell leukemia virus type-1, Jpn. J. Cancer Res., 76: 474-480, 1985.
7. Y. Yamada, Phenotypic and functional analysis of leukemic cells from 16 patients with adult T-cell leukemia/lymphoma, Blood, 61: 192-199, 1983.
8. K. Karube, K. Ohshima, T. Tsuchiya, T. Yamaguchi, R. Kawano, I. Suzumiya, A. Utsunomiya, M. Harada, and M. Kikuchi, Expression of FoxP3, a key molcule in CD4CD25 regulatory T cells, in adult T-cell leukaemia/lymphoma cells, Br. J. Haematol., 126: 81-84, 2004.
9. T. Kohno, Y. Yamada, N. Akamatsu, S. Kamihira, Y. Imaizumi, M. Tomonaga, and T. Matsuyama, Possible origin of adult T-cell leukemia/lymphoma cells from human T lymphotropic virus type-1-infected regulatory T cells, Cancer Sci., 96: 527-533, 2005.
10. Y. Yamada, Cell Biology of Adult T-Cell Leukemia-Lymphoma (ATLL). Recent Advances in Hematology 1. Kerala, India: Global Research Network, pp. 27-34, 2006.
11. M. Shimoyama and members of the Lymphoma Study Group (1984-1987), Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-1987), Br. J. Haematol., 79: 428-437, 1991.
12. Y. Yamada and M. Tomonaga, The current status of therapy for adult T-cell leukaemia-lymphoma in Japan, Leuk. Lymphoma, 44: 611-618, 2003.
13. T. Okamoto, Y. Ohno, S. Tsugane, S. Watanabe, M. Shimoyama, K. Tajima, M. Miwa, and K. Shimotohno, Multistep carcinogenesis adult T-cell, leukemia, Jpn. J. Cancer Res., 80: 191-195, 1989.
14. M. Yoshida, Molecular Biology of HTLV-1: Pleiotropic Function of Tax Protein in Cell Regulation. Gann Monograph on Cancer Research No. 50, Tokyo, Japan: Japan Scientific Societies Press, pp. 11-18, 2003.
15. M. Seiki, S. Hattori, Y. Hirayama, and M. Yoshida, Human adult T-cell leukemia virus: complete nucleotide sequence of the provirus genome integrated in leukemia cell DNA, Proc. Natl. Acad. Sci. U.S.A., 80: 3618-3622, 1983.
16. R. Grassmann, M. Aboud, and K.T. Jeang, Molecular mechanisms of cellular transformation by HTLV-1 tax, Oncogene, 24: 5976-5985, 2005.
17. S.C. Sun and S. Yamaoka, Activation of NF-B by HTLV-1 and implications for cell transformation, Oncogene, 24: 5952-5964, 2005.
18. H. Iha, K.V. Kibler, V.R. Yedavalli, J.M. Peloponese, K. Haller, A. Miyazato, T. Kasai, and K.T. Jeang, Segregation of NF-kappaB activation through NEMO/IKKgamma by Tax and TNFalpha: implications for stimulus-specific interruption of oncogenic signaling, Oncogene, 22: 8912-8923, 2003.
19. G. Xiao, M.E. Cvijic, A. Fong, E.W. Harhaj, M.T. Uhlik, M. Waterfield, and S.C. Sun, Retroviral oncoprotein Tax induces processing of NF-kappaB2/p100 in T cells: evidence for the involvement of IKKalpha, EMBO J., 20: 6805-6815, 2001.
20. INK4A and counteracts its inhibitory activity towards CDK4, EMBO J., 15: 1607-1614, 1996.
21. K.T. Jeang, S.G. Widen, O.J.T. Semmes, and S.H. Wilson, HTLV-1 trans-activator protein, tax, is a trans-repressor of the human beta-polymerase gene, Science, 247: 1082-1084, 1990.
22. S. Ressler, G.F. Morris, and S.J. Marriott, Human T-cell leukemia virus type 1 Tax transactivates the human proliferating cell nuclear antigen promoter, J. Virol., 71: 1181-1190, 1997.
23. S.Y. Kao and S.J. Marriott, Disruption of nucleotide excision repair by the human T-cell leukemia virus type 1 Tax protein, J. Virol., 73: 4299-4304, 1999.
24. J.C. Mulloy, T. Kislvakova, A. Cereseto, L. Casareto, A. LoMonico, J. Fullen, M.V. Lorenzi, A. Cara, C. Nicot, C. Giam, and G. Franchini, Human T-cell lymphotropic/lukemia virus type 1 Tax abrogates p53-induce cell cycle arrest and apoptosis through its CREB/ATF functional domain, J. Virol., 72: 8852-8860, 1998.
25. T. Suzuki, M. Uchida-Toita, and M. Yoshida, Tax protein of HTLV-1 inhibits CBP/p300-mediated transcription by interfering with recruitment of CBP/p300 onto DNA element of E-box or p53 binding site, Oncogene, 18: 4137-4143, 1999.
26. D.Y. Jin, F. Spencer, and K.T. Jeang, Human T cell leukemia virus type 1 oncoprotein Tax targets the human mitotic checkpoint protein MAD1, Cell, 93: 81-91, 1998.
27. B. Liu, S. Hong, Z. Tang, H. Yu, and C.Z. Giam, HTLV-1 Tax directly bind the Cdc-20-associated anaphase-promoting complex and activates it ahead of schedule, Proc. Natl. Acad. Sci. U.S.A., 102: 63-68, 2005.
28. N. Kamada, M. Sakurai, K. Miyamoto, I. Sanada, N. Sadamori, S. Fukuhara, S. Abe, Y. Shiraishi, T. Abe, Y. Kaneko, and M. Shimoyama, Chromosome abnormalities in adult T-cell leukemia/lymphoma: a karyotype review committee report, Cancer Res., 52: 1481-1493, 1992.
29. T. Itoyama, R.S. Chaganti, Y. Yamada, K. Tsukasaki, S. Atogami, H. Nakamura, M. Tomonaga, K. Ohshima, M. Kikuchi, and N. Sadamori, Cytogenetic analysis and clinical significance in adult T-cell leukemia/lymphoma: a study of 50 cases from the human T-cell leukemia virus type-1 endemic area, Nagasaki, Blood, 97: 3612-2620, 2001,
30. J. Yasunaga and M. Matsuoka, Human T-cell leukemia virus type 1 induces adult T-cell leukemia: from clinical aspects to molecular mechanisms, Cancer Control, 14: 133-140, 2007.
31. S. Takeda, M. Maeda, S. Morikawa, Y. Taniguchi, J. Yasunaga, K. Nosaka, Y. Tanaka, and M. Matsusaka, Genetic and epigenetic inactivation of tax gene in adult T-cell leukemia cells, Int. J. Cancer, 109: 559-567, 2004.
32. T. Koiwa, A. Hamano-Usami, T. Ishida, A. Okayama, K. Yamaguchi, S. Kamihira, and T. Watanabe, 5′-long terminal repeat-selective CpG methylation of latent human T-cell leukemia virus type 1 provirus in vitro and in vivo, J. Virol., 76: 9389-9397, 2002.
33. Y. Furukawa, R. Kubota, M. Tara, S. Izumo, and M. Osame, Existence of escape mutant in HTLV-1 tax during the development of adult T-cell leukemia, Blood, 97: 987-993, 2001.
34. J.M. Mesnard, B. Barbeau, and C. Devaux, HBZ, a new important player in the mystery of adult T-cell leukemia, Blood, 108: 3979-3982, 2006.
35. G. Gaudray, F. Gachon, J. Basbous, M. Biard-Piechaczyk, C. Devaux, and J.M. Mesnard, The complementary strand of the human T-cell leukemia virus type 1 RNA genome encodes a bZIP transcription factor that down-regulates viral transcription, J. Virol., 76: 12813-12822, 2002.
36. Y. Satou, J. Yasunaga, M. Yoshida, and M. Matsuoka, HTLV-1 basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells, Proc. Natl. Acad. Sci. U.S.A., 103: 720-725, 2006.
37. K. Murata, T. Hayashibara, K. Sugahara, A. Uemura, T. Yamaguchi, H. Harasawa, H. Hasegawa, K. Tsuruda, T. Okazaki, T. Koji, T. Miyanishi, Y. Yamada, and S. Kamihira, A novel alternative splicing isoform of human T-ell leukemia virus type 1 bZIP factor (HBZ-SI) targets distinct subnuclear localization, J. Virol., 80: 2495-2505, 2006.
38. M.H. Cavanagh, S. Landry, B. Audet, C. Arpin-Andre, P. Hivin, M.E. Pare, J. Thete, E. Watel, S.J. Marriott, J.M. Mesnard, and B. Barbeau, HTLV-1 antisense transcripts initiating in the 3′LTR are alternatively spliced and polyadenylated, Retrovirology, 3: 15, 2006.
39. J. Basbous, C. Arpin, Gaudray, M. Piechaczyk, C. Devaux, and J.M. Mesnard, The HBZ factor of human T-cell leukemia virus type 1 dimerizes with transcription factors JunB and c-Jun and modulates their transcriptional activity, J. Biol. Chem., 278: 43620-43627, 2003.
40. S. Thebault, J. Basbous, P. Hivin, C. Devaux, and J.M. Mesnard, HBZ interacts with JunD and stimulates its transcriptional activity, FEBS Lett., 56: 165-170, 2004.
41. J. Matsumoto, T. Ohshima, O. Isono, and K. Shimotohno, HTLV-1 HBZ suppresses AP-1 activity by impairing both the DNA-binding ability and the stability of c-Jun protein, Oncogene, 24: 1001-1010, 2005.
42. M. Matsuoka and K.T. Jeang, Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation, Nat. Rev. Cancer, 7: 270-280, 2007.
43. J. Arnold, B. Yamamoto, M. Li, A.J. Phipps, I. Younis, M.D. Lairmore, and P.L. Green, Enhancement of infectivity and persistence in vivo by HBZ, a natural antisense coded protein of THLV-1, Blood, 107: 3976-3982, 2006.
44. C.J. Sherr and J.M. Roberts, CDK inhibitors: positive and negative regulators of G1-phase progression, Genes Dev., 13: 1501-1512, 1999.
45. M. Malumbres and M. Barbacid, To cycle or not to cycle: a critical decision in cancer, Nat. Rev. Cancer, 1: 222-231, 2001.
46. C.J. Sheer and F. McCormick, The RB and p53 pathways in cancer, Cancer Cell, 2: 103-112, 2002.
47. W.S. El-Deiry, Regulation of p53 downstream genes, Sem. Cancer Biol., 8: 345-357, 2003.
48. B. Vogelstein and K.W. Kinzler, Cancer genes and the pathways they control, Nat. Med., 10: 789-799, 2004.
49. M. Hollstein, B. Vogelstein, and C.C. Harris, p53 mutations in human cancers, Science, 253: 49-53, 1991.
50. P. Hainaut and M. Hollstein, p53 and human cancer: the first ten thousand mutations, Adv. Cancer Res., 77: 81-137, 2000.
51. T. Nobori, K. Miura, D.J. Wu, A. Lois, K. Takabayashi, and D.A. Carson, Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers, Nature, 368: 753-756, 1994.
52. A. Kamb, N.A. Gruis, J. Weaver-Feldhaus, Q. Liu, K. Harshman, S.V. Tavtigian, E. Stockert, R.S. Day III, B.E. Johnson, and M.H. Skolnick, A cell cycle regulator potentially involved in genesis of many tumor types, Science, 264: 436-440, 1994.
53. Y. Hatta, T. Hirama, C.W. Miller, Y. Yamada, M. Tomonaga, and H.P. Koeffler, Homozygous deletions of p15(MTS2) and p16 (CDKN2/MTS1) genes in adult T-cell leukemia, Blood, 85: 2699-2704, 1995.
54. Y. Yamada, Y. Hatta, K. Murata, K. Sugahara, S. Ikeda, M. Mine, T. Maeda, Y. Hirakata, S. Kamihira, K. Tsukasaki, et al. Deletions of p15 and/or p16 genes as a poor-prognosis factor in adult T-cell leukemia, J. Clin. Oncol., 15: 1778-1785, 1997.
55. Y. Takasaki, Y. Yamada, K. Sugahara, T. Hayashi, N. Dateki, H. Harasawa, S. Kawabata, H. Soda, S. Ikeda, M. Tomonaga, and S. Kamihira, Interruption of p16 gene expression in adult T-cell leukaemia/lymphoma: clinical correlation, Br. J. Haematol., 122: 253-259, 2003.
56. H. Nagai, T. Kinoshita, J. Imamura, Y. Murakami, K. Hayashi, K. Mukai, S. Ikeda, K. Tobinai, H. Saito, M. Shimoyama, and K. Shimotohno, Genetic alteration of p53 in some patients with adult T-cell leukemia, Jpn. J. Cancer Res., 82: 1421-1427, 1991.
57. S. Sugito, K. Yamato, Y. Sameshima, J. Yokota, S. Yano, and I. Miyoshi, Adult T-cell leukemia: structures and expression of the p53 gene, Int. J. Cancer, 49: 880-885, 1992.
58. A. Sakashita, T. Hattori, C.W. Miller, H. Suzushima, N. Asou, K. Takatsuki, and H.P. Keoeffler, Mutations of the p53 gene in adult T-cell leukemia, Blood, 79: 477-480, 1992.
59. S. Nishimura, N. Asou, H. Suzushima, T. Okubo, T. Fujimoto, M. Osato, H. Yamasaki, L. Lisha, and K. Takatsuki, p53 gene mutation and loss of heterozygosity are associated with increased risk of disease progression in adult T cell leukemia, Leukemia, 9: 598-604, 1995.
60. M. Tawara, S.J. Hogerzeil, Y. Yamada, Y. Takasaki, H. Soda, H. Hasegawa, K. Murata, S. Ikeda, Y. Imaizumi, K. Sugahara, K. Tsuruda, K. Tsukasaki, M. Tomonaga, Y. Hirakata, and S. Kamihira, Impact of p53 aberration on the progression of adult T-cell leukemia/lymphoma, Cancer Lett., 234: 249-255, 2006.
61. D.E. Quelle, F. Zindy, R.A. Ashmun, and C.J. Sherr, Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest, Cell, 83: 993-1000, 1995.
62. Arf, Proc. Natl. Acad. Sci. U.S.A., 94: 669-673, 1997.
63. T. Kamijo, F. Zindy, M.F. Roussel, D.E. Quelle, J.R. Downing, R.A. Ashmun, G. Grosveld, and C.J. Sherr, Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF, Cell, 91: 649-659, 1997.
64. M.S. Hayden and S. Ghosh, Signaling of NF-kappaB, Genes Dev., 18: 2195-2224, 2004.
65. N. Mori, M. Fujii, S. Ikeda, Y. Yamada, M. Tomonaga, D.W. Ballard, and N. Yamamoto, Constitutive activation of NF-κB in primary adult T-cell leukemia cells, Blood, 93: 2360-2368, 1999.
66. N. Mori, Y. Yamada, S. Ikeda, Y. Yamasaki, K. Tsukasaki, Y. Tanaka, M. Tomonaga, N. Yamamoto, and M. Fujii, Bay 11-7082 inhibits transcription factor NF-kappaB and induces apoptosis of HTLV-1-infected T-cell lines and primary adult T-cell leukemia cells, Blood, 100: 1828-1834, 2002
67. M.Z. Dewan, K. Terashima, M. Taruishi, H. Hasegawa, M. Ito, Y. Tanaka, N. Mori, T. Sata, Y. Koyanagi, M. Maeda, et al. Rapid tumor formation of human T-cell leukemia virus type 1-infected cell lines in novel NOD-SCID/gammac(null) mice: suppression by an inhibitor against NF-kappaB, J. Virol., 77: 5286-5294, 2003.
68. A. Ariga, J. Namekawa, N. Matsumoto, J. Inoue, and K. Umezawa, Inhibition of tumor necrosis factor-alpha-induced nuclear translocation and activation of NF-kappaB by dehydroxymethylepoxyquinomicin, J. Biol. Chem., 277: 24625-24630, 2002.
69. M. Watanabe, T. Ohsugi, M. Shoda, T. Ishida, S. Aizawa, M. Maruyama-Nagai, A. Utsunomiya, S. Koga, Y. Yamada, S. Kamihira, et al., Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-κB, as a strategy for chemoprevention and therapy of adult T-cell leukemia, Blood, 106: 2462-2471, 2005.
70. M.Z. Dewan, J.N. Uchihara, K. Terashima, M. Honda, T. Seto, M. Ito, N. Fujii, K. Uozumi, K. Tsukasaki, M. Tomonaga, et al., Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir, Blood, 107: 716-724, 2006.
71. Y. Kfoury, R. Nasr, O. Hermine, H. de The, and A. Bazarbachi, Proapoptotic regimes for HTLV-1-transformed cells: targeting Tax nd the NF-κB pathway, Cell Death Differ., 12: 871-877, 2005.
72. O. Hermine, H. Dombret, J. Poupon, B. Arnulf, F. Lefrere, P. Rousselot, G. Damaj, R. Delarue, J.P. Fermand, J.C. Brouet, et al., Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma, Hematol. J., 5: 130-134, 2004.
73. M. Tomita, H. Kawakami, J.N. Uchihara, T. Okudaira, M. Matsuda, N. Takasu, T. Matsuda, T. Ohta, Y. Tanaka, K. Ohshiro, and N. Mori, Curcumin (diferuloylmethane) inhibits constitutive active NF-kappaB, leading to suppression of cell growth of human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells, Int. J. Cancer, 118: 765-772, 2006.
74. Y. Satou, K. Nosaka, Y. Koya, J.I. Yasunaga, S. Toyokuni, and M. Matsuoka, Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro, Leukemia, 18: 1357-1363, 2004.
75. C. Nishioka, T. Ikezoe, J. Yang, H.P. Koeffler, and H. Taguchi, Fludarabine induces apoptosis of human T-cell leukemia virus type 1-infected T cells via inhibition of the nuclear factor-kappa B signal pathway, Leukemia, 21: 1044-1049, 2007.
76. A. Zslotnik and O. Yoshie, Chemokines: a new classification system and their role in immunity, Immunity, 12: 121-127, 2000.
77. J.J. Campbell, G. Haraldsen, J. Pan, J. Rottman, S. Qin, P. Ponath, D.P. Andrew, R. Warnke, N. Ruffing, N. Kassam, L. Wu, and E.C. Butcher, The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells, Nature, 400: 776-780, 1999.
78. O. Yoshie, R. Fujisawa, T. Nakayama, H. Harasawa H. Tago, D. Izawa, K. Hieshima, Y. Tatsumi, K. Matsushima, H. Hasegawa, et al., Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells, Blood, 99: 1505-1511, 2002.
79. H. Harasawa, Y. Yamada, K. Hieshima, Z. Jin, T. Nakayama, O. Yoshie, K. Shimizu, H. Hasegawa, T. Hayashi, T. Imaizumi, et al., Survey of chemokine receptor expression reveals frequent co-expression of skin-homing CCR4 and CCR10 in adult T-cell leukemia/lymphoma, Leuk. Lymphoma, 47: 2163-2173, 2006.
80. T. Ishida, S. Iida, Y. Akatsuka, T. Ishii, M. Miyazaki, H. Komatsu, H. Inagaki, N. Okada, T. Fujita, K. Shitara, et al., The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-cell leukemia/lymphoma, Clin. Cancer Res., 10: 7529-7539, 2004.
81. S.R. Wiley, K Schooley, P.J. Smolak, W.S. Din, C.P. Huang, J.K. Nicholl, G.R. Sutherland, T.D. Smith, C. Rauch, C.A. Smith, and R.G. Goodwin, Identification and characterization of a new member of the TNF family that induces apoptosis, Immunity, 3: 673-682, 1995.
82. A. Ashkenazi, R.C. Pai, S. Fong, S. Leung, D.A. Lawrence, S.A. Marsters, C. Blackie, L. Chang, A.E. McMurtrev, A. Hebert, et al., Safety and antitumor activity of recombinant soluble Apo2 ligand, J. Clin. Invest., 104: 155-162, 1999.
83. H. Walczak, R.E. Miller, K. Ariail, B. Gliniak, T.S. Griffith, M. Kubin, W. Chin, J. Jones, A. Woodward, T. Le, et al., Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo, Nat. Med., 5: 157-163, 1999.
84. H.N. LeBlanc and A. Ashkenazi, Apo2/TRAIL and its death and decoy receptors, Cell Death Differ., 10: 66-75, 2003.
85. P. Marini, Drug evaluation: lexatumumab, an intravenous human agonistic mAb targeting TRAIL receptor 2, Curr. Opin. Mol. Ther., 8: 539-546, 2006.
86. A.W. Tolcher, M. Mita, N.J. Meropol, M. von Mehren, A. Patnaik, K. Padavic, M. Hill, T. Mays, T. McCoy, N.L. Fox, et al., Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis actor-related apoptosis-inducing ligand receptor-1, J. Clin. Oncol., 25: 1390-1395, 2007.
87. R.S. Herbst, D.S. Mendolson, S. Ebbinghaus, M.S. Gordon, P. O'Dwyer, G. Lieberman, J. Ing, R. Kurzrock, W. Novotny, and G. Eckhardt, A phase 1 safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer, ASCO Annual Meeting Proceedings Abstract No. 3013. J. Clin. Oncol., 25(Suppl): 124S, 2006.
88. H. Hasegawa, Y. Yamada, H. Harasawa, T. Tsuji, K. Murata, K. Sugahara, K. Tsuruda, S. Ikeda, Y. Imaizumi, M. Tomonaga, et al., Sensitivity of adult T-cell leukaemia lymphoma cells to tumour necrosis factor-related apoptosis-inducing ligand, Br. J. Haematol., 128: 253-265, 2004.
89. H. Hasegawa, Y. Yamada, K. Komiyama, M. Hayashi, M. Ishibashi, T. Yoshida, T. Sakai, T. Koyano, T.S. Kam, K. Murata, et al., Dihydroflavonol BB-1, an extract of natural plant Blumea balsamifera, abrogates TRAIL resistance in leukemia cells, Blood, 107: 679-688, 2006.
90. 12,14 prostaglandin J2 production, Blood, 110: 1664-1674, 2007.